Durvalumab consolidation therapy in patients with stage III small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
Durvalumab improves survival in LS-SCLC but lacks cost-effectiveness under current pricing in China. Drug costs and health utilities are critical determinants. Policy measures, such as price negotiation, risk-sharing agreements, or subgroup targeting, may enhance affordability. Balancing clinical benefits with economic burden is essential for optimizing durvalumab's role in LS-SCLC management.
Authors
- Bo Cai (ORCID: https://orcid.org/0000-0002-9208-4445)
- Hui Zhang (ORCID: https://orcid.org/0000-0001-6825-5649)
- Hong Wang (ORCID: https://orcid.org/0000-0002-1300-9595)
- Liu Y (ORCID: https://orcid.org/0000-0002-4548-8324)
- Mengyi Wang (ORCID: https://orcid.org/0000-0002-9348-6876)
- Haonan Li (ORCID: https://orcid.org/0009-0004-1982-8710)
Institutions
- Guangdong Pharmaceutical University (CN)
- Peking University (CN)
- Peking University International Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.3389/fonc.2025.1643022
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Guangdong Pharmaceutical University